Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Bicycle Therapeutics Plc ADR (BCYC)

Bicycle Therapeutics Plc ADR (BCYC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Why Shares of Bicycle Therapeutics Were Rising on Monday Motley Fool - Mon Sep 11, 2023

The company said it is working with the FDA to structure a phase 2/3 trial for its bladder cancer therapy.

NVS : 94.36 (+1.93%)
BCYC : 23.45 (-4.25%)
Why Bicycle Therapeutics Stock Raced Ahead Today Motley Fool - Thu Jul 13, 2023

The company's latest attempt at capital raising seems to be having enviable success.

GS : 404.00 (+0.22%)
JEF : 42.17 (+1.57%)
BCYC : 23.45 (-4.25%)
Wall Street Analysts Think Bicycle Therapeutics PLC Sponsored ADR (BCYC) Could Surge 146.31%: Read This Before Placing a Bet Zacks - Thu May 4, 2023

The consensus price target hints at a 146.3% upside potential for Bicycle Therapeutics PLC Sponsored ADR (BCYC). While empirical research shows that this sought-after metric is hardly effective, an upward...

BCYC : 23.45 (-4.25%)
Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Business Wire - Thu May 4, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today...

BCYC : 23.45 (-4.25%)
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets Business Wire - Thu May 4, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced...

BCYC : 23.45 (-4.25%)
Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting Business Wire - Fri Apr 14, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today...

BCYC : 23.45 (-4.25%)
Bicycle Therapeutics Enhances Leadership Team with Key Appointments Business Wire - Mon Apr 3, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 23.45 (-4.25%)
Bicycle (BCYC) up on Collaboration With Novartis for Conjugates Zacks - Wed Mar 29, 2023

Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.

NVS : 94.36 (+1.93%)
APTX : 0.0960 (+3.11%)
BCYC : 23.45 (-4.25%)
ANVS : 10.06 (+2.13%)
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates Business Wire - Tue Mar 28, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 23.45 (-4.25%)
Bicycle Therapeutics to Participate in Upcoming Investor Conferences Business Wire - Tue Feb 28, 2023

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 23.45 (-4.25%)

Barchart Exclusives

Dividend Newcomers: Discover 3 Companies Starting To Share the Wealth Barchart - Fri Apr 19, 6:00PM CDT
Discover the potential of newly initiated dividends—start building your wealth with tomorrow's top dividend payers today! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot